ESR1 and neoplasm: One of the rare but clinically especially aggressive variants is the “triple-negative” subtype, i.e. where the tumor cells do not express 3 receptors commonly targeted in hormonal and immunotherapy: estrogen receptor, progesterone receptor, and ERBB2 (HER2) receptor.